Isomorphic Labs’ deals with Eli Lilly and Novartis carried $82.5 million of upfront payments, against up to $2.9 billion of milestone payments it could earn later, according to the two collaboration releases it published on 7 January 2024. Under the Lilly terms, Isomorphic receives $45 million upfront from Lilly and is eligible for up to $1.7 billion in performance-based milestones; under the Novartis terms, it receives $37.5 million from Novartis and is eligible for up to $1.2 billion.
Our number: about 2.8% of the deals’ combined potential value of $2.98 billion, excluding royalties, was due upfront, by our arithmetic. The milestone ceiling is about 35 times the upfront cash. The $5 billion Series C Isomorphic announced on 17 November is about 1.7 times that whole milestone ceiling.
Business Pill · Royalties
An evergreen Business Engineer explainer on royalties: paying each time you use someone else’s idea. It teaches the general idea only and does not discuss Isomorphic Labs.
The key insight: As we read the releases, almost all of the value in Isomorphic’s two disclosed pharma deals is contingent: $82.5 million was paid upfront and up to $2.9 billion depends on performance-based milestones, so about 2.8% of the potential value was due upfront, by our arithmetic.
What Each Deal Pays
Under the Lilly agreement, Isomorphic will partner with Lilly to discover small molecule therapeutics against multiple targets, the release says. On top of the $45 million and the milestones, it lists “tiered royalties of up to low double digits on net sales.”
The Novartis release covers small molecule therapeutics against three undisclosed targets. Besides the $37.5 million upfront, it says Novartis is funding select research costs, and that royalties run “from mid-single up to low double-digit royalties on net sales.”
Both milestone figures exclude the upfront payment and any royalties, according to the releases. In its 7 January 2024 post, Isomorphic said the two partnerships had the potential to be worth nearly $3 billion to it, excluding any royalties.

The Expansion and the Third Partner
On 18 February 2025, Isomorphic said Novartis had agreed to add up to three additional research programs “on the same financial terms as the original agreement.” The release gives no new dollar figure.
In January 2026 Isomorphic announced a cross-modality, multi-target research collaboration with Johnson & Johnson. The post we read describes the scope, including large molecule and biologics design, and does not state financial terms.
Isomorphic says it runs partnered programs alongside wholly-owned internal programs. Its 17 November release says the momentum is yielding positive preclinical results for internal programs in oncology and immunology and with partners.
The Same Shape Across AI Drug Deals
By our arithmetic, the Lilly deal carried about 2.6% of its potential value upfront and the Novartis deal about 3.0%. On 15 October we reported that insitro would receive $40 million upfront from AstraZeneca and up to approximately $1.46 billion in milestones, which is about 2.7% upfront on the same basis.
In the week of 20 October, drugmakers attached about $3.8 billion of potential milestone payments to AI partners, by our arithmetic, including a METiS TechBio deal with Lilly worth up to about $1.1 billion in milestones.
What the $5 Billion Is Measured Against
The $5 billion round is about 60 times the $82.5 million of upfronts and about 1.7 times the $2.9 billion milestone ceiling, by our arithmetic. Milestones are paid only if programs reach performance-based goals, the releases say, while the Series C is cash raised from investors.
Menlo Ventures estimates that pharma spent $600 million externally on AI in drug discovery in 2026, up 28.6 times on its chart. By our arithmetic, Isomorphic’s one round is about 8.3 times that estimate.
The Structural Read
As we read it, the $5 billion Series C changes which money pays for the work: equity raised from investors is about 1.7 times the full milestone ceiling the two deals could pay, by our arithmetic.
As we read the February 2025 release, the Novartis expansion added programs rather than headline money: up to three more programs on the same financial terms as the original agreement, with no new dollar figure stated.
Fiona Marshall, President of Biomedical Research at Novartis, in Isomorphic Labs’ release, 18 February 2025
“We selected particularly challenging targets for our initial programs with Isomorphic because we appreciate the remarkable potential of their AI-driven capabilities in drug discovery and design.”
Three Implications
FOR DRUGMAKERS The insitro and AstraZeneca deal we reported in October shows the same split, about 2.7% upfront on our arithmetic, so most of the money in these deals is paid only if programs advance.
FOR AI DRUG-DISCOVERY COMPANIES Menlo Ventures estimates pharma spent $600 million externally on AI in drug discovery in 2026; Isomorphic’s one round is about 8.3 times that, by our arithmetic.
RELATED Isomorphic Labs raised $5 billion in a Series C on 17 November, 2.4 times its May round.
The Business Engineer Lens
This story maps onto the Business Engineer framework The AI Embedding Business Model.
The framework says: “In the embedding era, value comes from what the software connects to.”
As we read it, Isomorphic’s deal terms price that connection: small upfront payments, with most of the value tied to milestones in partners’ programs. The framework predates these deals and does not discuss Isomorphic.

What Is Not Established
The releases we read do not say how much of the milestone money, if any, Isomorphic has earned since January 2024, or which programs have met performance goals. The financial terms of the Johnson & Johnson collaboration are not in the post we read.
The Novartis expansion is on the same financial terms as the original agreement, the company says, but the release does not state whether that raises the $1.2 billion milestone figure. Isomorphic, Lilly, Novartis and Johnson & Johnson were not contacted for this piece.
The Bottom Line
Isomorphic Labs’ two disclosed pharma deals carried $82.5 million of upfront payments against up to $2.9 billion of milestones, about 2.8% upfront by our arithmetic. The $5 billion Series C is about 1.7 times that entire milestone ceiling.
95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. We read Isomorphic Labs’ 7 January 2024 Eli Lilly and Novartis release PDFs and its 18 February 2025 Novartis expansion release in full, plus its January 2024 and January 2026 Johnson & Johnson posts, its partnerships page and its 17 November 2026 Series C release. The insitro, METiS and Menlo figures come from our earlier pieces, linked. Totals, ratios and percentages are our arithmetic. Not investment advice; for information only.
Sources: Isomorphic Labs Lilly release (PDF), 7 Jan 2024 · Isomorphic Labs Novartis release (PDF), 7 Jan 2024 · Isomorphic Labs Novartis expansion release (PDF), 18 Feb 2025 · Isomorphic Labs post, 7 Jan 2024 · Isomorphic Labs J&J post, Jan 2026 · Isomorphic Labs partnerships page · Isomorphic Labs Series C release (PDF), 17 Nov 2026









